Imunobiológicos no tratamento das doenças alérgicas: revisão sistemática da literatura.

Abstract

Immunobiologicals are emerging as an alternative to some serious allergic conditions, especially allergic asthma and atopic dermatitis (AD). Objective: To verify that omalizumab, benralizumab and dupilumab compared to placebo contribute to clinical improvement in patients with asthma and atopic dermatitis who do not respond well to conventional treatments. Method: Systematic review with secondary analysis of placebo-controlled, double-blind, randomized controlled trial data on immunobiologicals used in the treatment of asthma and atopic dermatitis, using the descriptors: “omalizumabalergia”, “benralizumabalergia” e “dupilumabalergia” and their englishcorrespondentes in the virtual databases: LILACS, MEDLINE, Pubmed and Scielo in portuguese, english e Spanish. Results: In the selected clinical trials, it was observed that omalizumab, benralizumab and dupilumab showed good response for asthma and moderate to severe AD control compared with the placebo group. In addition, we observed a higher prevalence of adverse events in the placebo group, but found a significant occurrence of airway disorders and injection site reaction. Conclusion: It was observed, through the analysis of the selected clinical trials, that moderate to severe asthma and atopic dermatitis can be well controlled with complementary immunobiological therapy and with the analysis of adverse effects, safety with omalizumab, benralizumab and dupilumab is demonstrated.